Hashimoto Yuichi, Umahara Takahiko, Hanyu Haruo, Iwamoto Toshihiko, Matsuoka Masaaki
a Department of Pharmacology , Tokyo Medical University , Tokyo , Japan.
c Department of Geriatric Medicine , Tokyo Medical University , Tokyo , Japan.
Neurol Res. 2017 Sep;39(9):767-772. doi: 10.1080/01616412.2017.1335458. Epub 2017 Jun 7.
Calmodulin-like skin protein (CLSP) is a secreted peptide that inhibits neuronal cell death, linked to Alzheimer's disease (AD), by binding to the heterotrimeric humanin receptor and activating an intracellular survival pathway. CLSP is only expressed in skin keratinocytes and related epithelial cells, circulates in the blood stream, and passes the blood-cerebrospinal fluid (CSF) barrier. In the current study, we addressed the issues as to whether CLSP functions in the central nervous system and whether the concentration of CLSP is reduced in the CSFs of AD patients.
Mice were intraperitoneally injected with 5 nmol of recombinant human CLSP. At 1h after the injection, the mice were sacrificed for the analysis of the existence of human CLSP in blood and interstitial fluid (ISF)-containing brain samples. Using postmortem CSF samples, we next determined the concentrations of CLSP in CSFs of human AD and control cases.
Intraperitoneally administered recombinant human CLSP circulated in the blood stream and reached the brain interstitial fluid. The concentrations of CLSP in CSFs of human AD and control cases are sufficient to exhibit the CLSP activity. Although the concentrations of CLSP in CSFs were not significantly different between AD and control cases, the concentrations of CLSP are lower in the AD cases with the apolipoprotein E4 genotype than in the AD cases without the apolipoprotein E4 genotype.
The first result indicates that CLSP enters the central nervous system through the blood-brain barrier. The second result suggests that CLSP functions in the human brains. The third result may exclude the possibility that the downregulation of the CLSP level is involved in the AD pathogenesis. The last result may contribute to the better understanding of the AD pathogenesis from the standpoint of the apolipoprotein E genotype.
类钙调蛋白皮肤蛋白(CLSP)是一种分泌肽,通过与异源三聚体人胰岛素受体结合并激活细胞内生存途径来抑制与阿尔茨海默病(AD)相关的神经元细胞死亡。CLSP仅在皮肤角质形成细胞和相关上皮细胞中表达,在血流中循环,并通过血脑脊髓液(CSF)屏障。在本研究中,我们探讨了CLSP是否在中枢神经系统中发挥作用以及AD患者脑脊液中CLSP浓度是否降低的问题。
给小鼠腹腔注射5 nmol重组人CLSP。注射后1小时,处死小鼠以分析血液和含脑间质液(ISF)样本中是否存在人CLSP。接下来,我们使用死后脑脊液样本测定了人类AD和对照病例脑脊液中CLSP的浓度。
腹腔注射的重组人CLSP在血流中循环并到达脑间质液。人类AD和对照病例脑脊液中CLSP的浓度足以发挥CLSP活性。虽然AD和对照病例脑脊液中CLSP的浓度没有显著差异,但载脂蛋白E4基因型的AD病例中CLSP的浓度低于无载脂蛋白E4基因型的AD病例。
第一个结果表明CLSP通过血脑屏障进入中枢神经系统。第二个结果表明CLSP在人脑中发挥作用。第三个结果可能排除了CLSP水平下调参与AD发病机制的可能性。最后一个结果可能有助于从载脂蛋白E基因型的角度更好地理解AD发病机制。